Two acquisitions on the same day: OpenAI buys "Narrative," Anthropic buys "Barrier"

null

On April 2, OpenAI and Anthropic each announced an acquisition. OpenAI bought the tech livestream program TBPN, while Anthropic spent about $400 million in stock to acquire the AI biotech startup Coefficient Bio. Both companies are sprinting for an IPO by the end of 2026, but their shopping lists point to completely different anxieties.

15 deals vs 3 deals. This is the number of acquisitions each of OpenAI and Anthropic completed over the past three years.

According to Crunchbase, since 2023 OpenAI has completed 15 acquisitions across seven areas: hardware, enterprise services, developer tools, healthcare, security, media, and consumer. Just in the first three months of 2026 alone, it completed six deals. The disclosed deal totals exceed $7.7 billion, with the largest being the May 2025 acquisition of io, an AI hardware company founded by former Apple designer Jony Ive, for $6.5 billion.

Anthropic has only done 3 deals. In December 2025, it acquired the JavaScript runtime Bun to fill in the underlying infrastructure for Claude Code. According to an official Anthropic announcement, at the same time as the Bun acquisition, Claude Code’s annualized revenue disclosed reached $1 billion. In February 2026, it acquired the computer use agent startup Vercept to strengthen Claude’s autonomous operations capabilities. On April 2, it acquired Coefficient Bio to move into its life-sciences R&D pipeline. Each deal precisely maps to a technical layer in Claude’s product stack.

Notably, OpenAI also had one attempted deal that fell through. In May 2025, OpenAI reached an acquisition intent of $3 billion with the code editor Windsurf (formerly Codeium), but according to an IT Pro report, due to IP clauses in Microsoft’s contract, OpenAI was unable to protect Windsurf’s technology from being obtained by Microsoft, and the deal broke down in July. This failed attempt also reflects a structural constraint of OpenAI’s “breadth procurement” model.

This difference in deal density is not a coincidence. It reflects the two companies’ fundamentally different revenue structures—and thus their different anxieties.

Revenue structure determines acquisition direction

Sacra estimates that OpenAI’s annualized revenue in February 2026 is about $25 billion, roughly 60% coming from the consumer side (ChatGPT subscriptions) and 40% from the enterprise side. The 15.5 million paying users are the core base of OpenAI’s revenue. For a company about to IPO, an overly high share from the consumer side means that public sentiment directly affects the valuation narrative.

This helps explain why OpenAI wants to buy TBPN. As Axios reports, TBPN is a daily livestream tech talk show with $5 million in ad revenue in 2025 and a target of $30 million-plus in 2026. After acquiring it, OpenAI keeps editorial independence, while hiring former Postmates executive Dylan Abruscato to handle ad monetization. The logic of buying a tech podcast is not about its revenue; it’s about its ability to consistently shape the public discussion framework around AI topics.

Anthropic’s anxiety points in a completely different direction. Citing Ramp data, Sherwood News reports that Anthropic currently captures 73% of the market share of first-time AI purchasing enterprise customers; 10 weeks ago, that number was 50%. According to a SaaStr report, about 80% of Anthropic’s revenue comes from the enterprise side. For enterprise customers, choosing an AI vendor is a decision with very high switching costs. Anthropic’s IPO narrative needs to prove that these enterprise customers won’t leave.

Three moves over six months

Coefficient Bio was not an impulsive acquisition. Put it into the sequence of Anthropic’s actions over the past half year, and the logic is clear.

In October 2025, Anthropic released Claude for Life Sciences, integrating scientific research databases such as PubMed and UniProt so that Claude can assist with literature reviews and experiment design. In January 2026, at JPM26, it released Claude for Healthcare, securing HIPAA compliance certification and formally entering the healthcare system. On April 2, it acquired Coefficient Bio to gain end-to-end AI capabilities for drug R&D.

Over six months, it moved from the tool integration layer to the compliance access layer, and then to the R&D pipeline layer. According to a Newcomer report, Coefficient Bio was founded only eight months ago, has fewer than 10 employees, and is held at about 50% by the venture capital firm Dimension. Anthropic completed the acquisition with about $400 million in stock, and Dimension, in its letter to LPs, claims that the investment’s IRR is 38,513%.

That figure itself shows that Anthropic isn’t buying a company’s revenue or products, but a team plus an industry entry. According to Anthropic’s official reporting and RD World reports, pharma companies including Sanofi, Novo Nordisk, AbbVie, and Genmab are already using Claude’s life-sciences tools. Novo Nordisk’s case is especially typical: the time to process clinical research documents shrank from more than 10 weeks to 10 minutes.

Two balance sheets, the same countdown

According to reports from WinBuzzer and The Tech Portal, Anthropic has already hired Goldman Sachs and JPMorgan Chase to lead the underwriting, targeting an earliest IPO in October 2026 and raising more than $60 billion. OpenAI’s target is Q4 2026 or Q1 2027, with a valuation close to $1 trillion. According to Tom Tunguz’s analysis, if OpenAI, Anthropic, and SpaceX all IPO in the same year, just these three could absorb more than $3 trillion in market liquidity.

Both companies are making their final strategic adjustments ahead of the IPO. According to CNBC, OpenAI CEO Fidji Simo announced internally that it would cut Sora, the Atlas browser, hardware projects, and the instant checkout function, saying the company is “like entering a red alert,” and that it needs to focus on enterprise and agent products. Anthropic’s path, meanwhile, is to go deeper and deeper into vertical industries such as life sciences, using industry switching costs to lock in enterprise customers.

According to FinancialContent, OpenAI’s board is concerned that if Anthropic IPOs first, it would siphon away retail investors’ long-simmering AI investment enthusiasm. The two companies’ valuations differ by more than two times, but they are chasing the same pool of investors’ money. Two acquisitions on the same day—one buying a narrative machine, the other buying an industry entry point.